HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA And FTC Rules Indigenous To Native Advertising, Attorneys Caution

This article was originally published in The Tan Sheet

Executive Summary

Native advertising, advertising designed to blend in with nearby non-advertising content, is becoming more popular with the growth of digital marketing. But device-makers need to be cautious about using the medium in compliance with federal promotional rules.

You may also be interested in...



FTC Targets Unmasking 'Native Advertising' In Policy Update

FTC publishes enforcement policy statement addressing increases in native advertising and deceptively formatted ads. The statement explains how the commission will apply its current enforcement standards to target deceptive content, including promotions disguised as news stories, in violation of its policies.

FTC Commissioners Seem POM-Skeptical In Claims Hearing

“The idea that this company has built these health claims on bogus science is wrong,” says POM Wonderful counsel Edward Lazarus. But commissioners reviewing appeals of FTC’s challenge against POM’s claims for its pomegranate products appeared to believe the company made a number of implied disease claims.

News We’re Watching: Lung Preservation System Goes National, De Novo For MMI, Brazil’s ANVISA To Recognize Overseas Approvals

This week, Paragonix announced that its BAROguard lung preservation system is now available throughout the US; Brazil planned to leverage some foreign device approvals; Medical Microinstruments’ Symani Surgical System won de novo clearance; and the FDA updated its safety warnings for Essure and certain plastic syringes.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel